Neo-Endusix (Tenoxicam)

Tenoxicam, the active ingredient in Neo-Endusix, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an injectable solution for intramuscular and intravenous use. It is employed to relieve pain and reduce inflammation in conditions such as rheumatoid arthritis, osteoarthritis and acute musculoskeletal disorders.

GNH USA supplies Neo-Endusix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to healthcare institutions across global markets. Timely logistics and post‑delivery support are part of the service offering.

Tenoxicam is indicated for inflammatory and painful conditions affecting the musculoskeletal system.

Rheumatoid arthritis: reduces joint pain and swelling, improving functional ability. Osteoarthritis: alleviates chronic joint discomfort and stiffness. Acute musculoskeletal pain: provides rapid analgesia for injuries or post‑operative pain. Post‑operative pain: diminishes surgical site pain and inflammatory response. Ankylosing spondylitis: helps control spinal inflammation and pain.

Tenoxicam may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain that may be transient. - Headache: mild to moderate intensity, often resolving without intervention. - Dizziness: transient sensation of light‑headedness, especially after rapid administration. - Injection site reactions: erythema, swelling, or mild pain at the intramuscular or intravenous site.

Serious or Rare Side Effects: - Severe gastrointestinal ulceration or bleeding: may present with melena, hematemesis, or severe abdominal pain. - Renal impairment: sudden decrease in kidney function, manifested by elevated creatinine or reduced urine output. - Hypersensitivity reactions: rash, Stevens‑Johnson syndrome, or anaphylaxis requiring immediate medical attention.

When prescribing Tenoxicam, clinicians should consider several precautionary measures to minimise risk. - Assess renal function: avoid use in patients with severe renal impairment or acute kidney injury. - Monitor gastrointestinal risk: use with caution in individuals with history of ulcers or bleeding. - Evaluate cardiovascular status: NSAIDs may increase risk of thrombotic events in susceptible patients. - Check for concomitant anticoagulant therapy: heightened bleeding risk requires careful monitoring. - Avoid use in late pregnancy: safety data are insufficient for the third trimester. - Store below 25°C: keep in original container, protect from light and moisture.

Tenoxicam can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Lithium: NSAIDs may raise lithium serum concentrations, risking toxicity. - Methotrexate (high dose): reduced clearance leading to enhanced toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may diminish renal protective effects and worsen kidney function. - Diuretics: combined use can precipitate renal insufficiency. - Corticosteroids: heightened risk of gastrointestinal ulceration.